Benzodiazepines revisited-will we ever learn?

Addiction

Volumn 106, Issue 12, 2011, Pages 2086-2109

  Lader, Malcolm ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Abuse liability; Adverse effects; Benzodiazepines; Dependence; Efficacy; Extent of use

Indexed keywords

ANTIDOTE; BENZODIAZEPINE DERIVATIVE; FLUMAZENIL; HYPNOTIC SEDATIVE AGENT;

ACCIDENT; ADDICTION; AGE; ANXIETY DISORDER; CLINICAL PRACTICE; COGNITION; DRUG EFFECT; EPIDEMIOLOGY; EUROPE; FEMALE; HUMAN; INSOMNIA; MALE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY HEALTH CARE; PSYCHOMOTOR PERFORMANCE; REVIEW; STATISTICS; TIME; UNITED KINGDOM; WITHDRAWAL SYNDROME;

ACCIDENTS; AGE FACTORS; ANTIDOTES; ANXIETY DISORDERS; BENZODIAZEPINES; COGNITION; DRUG PRESCRIPTIONS; EPIDEMIOLOGIC METHODS; EUROPE; FEMALE; FLUMAZENIL; GREAT BRITAIN; HUMANS; HYPNOTICS AND SEDATIVES; MALE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; PSYCHOMOTOR PERFORMANCE; SLEEP INITIATION AND MAINTENANCE DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

EID: 80455160095     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2011.03563.x     Document Type: Article

References (277)

1. Baenninger A., Costa e Silva J. A., Hindmarch A., Moeller H. J., Rickels K. Good Chemistry: The Life and Legacy of Valium Inventor Leo Sternbach. New York: McGraw-Hill; 2004.
2. Ban T. A. In memory of three pioneers. Int J Neuropsychopharmacol 2006; 9: 475-7.
3. Froestl W. An historical perspective on GABAergic drugs. Future Med Chem 2011; 3: 163-75.
4. Mandrioli R., Mercolini L., Raggi M. A. Metabolism of benzodiazepine and non-benzodiazepine anxiolytic-hypnotic drugs: an analytical point of view. Curr Drug Metab 2010; 11: 815-29.
5. National Institute for Health and Clinical Excellence. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia. Technology Appraisal 77. London: National Institute for Health and Clinical Excellence; April 2004.
6. Millan M. J. The neurobiology and control of anxious states. Prog Neurobiol 2003; 70: 83-244.
7. Shin L. M., Liberzon I. The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology 2009; 35: 169-91.
8. Kerr D. I., Ong J. GABA-B receptors. Pharmacol Ther 1995; 67: 187-246.
9. Carter C. R., Kozuska J. L., Dunn S. M. Insights into the structure and pharmacology of GABA(A) receptors. Future Med Chem 2010; 2: 859-75.
10. Tan K. R., Rudolph U., Lüscher C. Hooked on benzodiazepines: GABAA receptor subtypes and addiction. Trends Neurosci 2011; 34: 188-97.
11. National Institute for Health and Clinical Excellence. Anxiety. Management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. Clinical Guideline 22. London: National Institute for Health and Clinical Excellence; December 2004.
12. Amato L., Minozzi S., Vecchi S., Davoli M. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev 2010; 3: CD005063. DOI: 10.1002/14651858.CD005063. Accessed 7 June 2011.
13. Riss J., Cloyd J., Gates J., Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand 2008; 118: 69-86.
14. Electronic Medicines Compendium. Summary of product characteristics, Diazepam Available at: (accessed 3 August 2011; archived by Webcite at).
15. Richey S. M., Krystal A. D. Pharmacological advances in the treatment of insomnia. Curr Pharm Des 2011; 17: 1471-5.
16. Srinivasan V., Brzezinski A., Pandi-Perumal S. R., Spence D. W., Cardinali D. P., Brown G. M. Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedative-hypnotics? Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 913-23.
17. Chessick C. A., Allen M. H., Thase M., Batista Miralha da Cunha A. B., Kapczinski F. F., de Lima M. S. etal. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev 2006; 3: CD006115.
18. Guaiana G., Barbui C., Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst Rev 2010; 12: CD006815.
19. Gao K., Sheehan D. V., Calabrese J. R. Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Exp Rev Neurother 2009; 9: 1147-58.
20. Vulink N. C. C., Figee M., Denys D. Review of atypical antipsychotics in anxiety. Eur Neuropsychopharmacol 2011; 21: 429-49.
21. Pfeiffer P. N., Ganoczy D., Zivin K., Valenstein M. Benzodiazepines and adequacy of initial antidepressant treatment for depression. J Clin Psychopharmacol 2011; 31: 360-4.
22. Cochrane Database Systematic Reviews. Cochrane.org/reviews/benzodiazepines (Accessed 7 June 2011).
23. Bond A. J., Lader M. H., Shotriya R. Comparative effects of a repeated dose regime of diazepam and buspirone on subjective ratings, psychological tests and the EEG. Eur J Clin Pharmacol 1983; 24: 463-7.
24. Curran H. V., Collins R., Fletcher S., Kee S. C. Y., Woods B., Iliffe S. Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life. Psychol Med 2003; 33: 1223-7.
25. Woods J. H., Katz J. L., Winger G. Benzodiazepine use, abuse and consequences. Pharmacol Rev 1992; 44: 151-34.
26. Wittenborn J. R., Flaherty C. F., McGough W. E., Nash R. J. Psychomotor changes during initial day of benzodiazepine medication. Br J Clin Pharmacol 1979; 7: 69S-76S.
27. Buffet-Jerrott S. E., Stewart S. H. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des 2002; 8: 45-58.
28. Lucki I., Rickels K., Geller A. M. Chronic use of benzodiazepines and psychomotor and cognitive test performance. Psychopharmacology 1986; 88: 426-33.
29. Golombok S., Moodley P., Lader M. Cognitive impairment in long-term benzodiazepine users. Psychol Med 1988; 18: 365-74.
30. Petursson H., Gudjonsson G., Lader M. Psychiatric performance during withdrawal from long-term benzodiazepine treatment. Psychopharmacology 1983; 81: 345-9.
31. Curran H. Tranquillising memories: a review of the effects of benzodiazepines on human memory. Biol Psychol 1986; 23: 179-213.
32. Curran H. V. Benzodiazepines, memory and mood: a review. Psychopharmacology 1991; 105: 1-8.
33. Bond A. J., Silveira J. C., Lader M. H. Effects of single doses of alprazolam alone and alcohol alone and in combination on psychological performance. Hum Psychopharmacol 1991; 6: 219-28.
34. Curran H. V., Gorenstein C. Differential effects of lorazepam and oxazepam on priming. Int Clin Psychopharmacol 1993; 8: 37-42.
35. Curran H. V., Bond A., O'Sullivan G., Bruce M., Marks I., Lelliot P. etal. Memory functions, alprazolam and exposure therapy: a controlled longitudinal trial of agoraphobia with panic disorder. Psychol Med 1994; 24: 969-76.
36. Gorenstein C., Bernik M. A., Pompeia S. Differential acute psychomotor and cognitive effects of diazepam on long-term benzodiazepine users. Int Clin Psychopharmacol 1994; 9: 145-53.
37. Barker M. J., Greenwood K. M., Jackson M., Crowe S. F. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 2004; 18: 37-48.
38. Verdoux H., Lagnaoui R., Begaud B. Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies. Psychol Med 2005; 35: 307-15.
39. Salzman C., Fisher J., Nobel K., Glassman R., Wolfson A., Kelley M. Cognitive improvement following benzodiazepine discontinuation in elderly nursing home residents. Int J Geriatr Psychiatry 1992; 7: 89-93.
40. Tata P. R., Rollings J., Collins M., Pickering A., Jacobson R. R. Lack of cognitive recovery following withdrawal from long-term benzodiazepine use. Psychol Med 1994; 24: 203-13.
41. Kilic C., Curran H. V., Noshirvani H., Marks I. M., Basoglu M. Long-term effects of alprazolam on memory: a 3.5 year follow-up of agoraphobic panic patients. Psychol Med 1999; 29: 225-31.
42. Wadsworth E. J. K., Moss S. C., Simpson S. A., Smith A. P. Psychotropic medication use and accidents, injuries and cognitive failures. Hum Psychopharmacol 2005; 20: 391-400.
43. Kallin K., Lundin-Olsson L., Jensen J., Nyberg L., Gustafson Y. Predisposing and precipitating factors for falls among older people in residential care. Public Health 2002; 116: 263-71.
44. Taylor S., McCracken C. F., Wilson K. C., Copeland J. R. Extent and appropriateness of benzodiazepine use. Results from an elderly urban community. Br J Psychiatry 1998; 173: 433-8.
45. Bartlett G., Abrahamowicz M., Grad R., Sylvestre M. P., Tamblyn R. Association between risk factors for injurious falls and new benzodiazepine prescribing in elderly persons. BMC Fam Pract 2009; 10: 1-8.
46. Ray W. A., Griffin M. R., Schaffner W., Baugh D. K., Melton L. J. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316: 363-9.
47. Sternbacka M., Jansson B., Leufman A., Romelsjo A. Association between use of sedatives or hypnotics, alcohol consumption, or other risk factors and single injurious fall or multiple injurious falls: a longitudinal general population study. Alcohol 2002; 28: 9-16.
48. Cumming R. G., Le Couteur D. G. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs 2003; 17: 825-37.
49. Leung S. Y. Benzodiazepines, opioids and driving: an overview of the experimental research. Drug Alcohol Rev 2011; 30: 281-6.
50. Ravera S., van Rein N., de Gier J. J., de Jong-van den Berg L. T. Road traffic accidents and psychotropic medication use in the Netherlands: a case-control study. Br J Clin Pharmacol 2011; doi: 10.1111/j.1365-2125.2011.03994.x. [Epub ahead of print].
51. Smink B. E., Egberts A. C., Lusthof K. J., Uges D. R., de Gier J. J. The relationship between benzodiazepine use and traffic accidents: a systematic literature review. CNS Drugs 2010; 24: 639-53.
52. Currie D., Hashemi K., Fothergill J., Findlay A., Harris A., Hindmarch I. The use of antidepressants and benzodiazepines in the perpetrators and victims of accidents. Occup Med 1995; 45: 323-5.
53. Skegg D. C. C., Richards S. M., Doll R. Minor tranquillisers and road accidents. BMJ 1979; 1: 917-9.
54. Thomas R. E. Benzodiazepine use and motor vehicle accidents. Systematic review of reported association. Can Fam Physician 1998; 44: 799-808.
55. Barbone F., McMahon A. D., Davey P. G., Morris A. D., Reid I. C., McDevitt D. G. etal. Association of road-traffic accidents with benzodiazepine use. Lancet 1998; 352: 1331-6.
56. Hemmelgarn B., Suissa S., Huang A., Boivin J. F., Pinard G. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA 1997; 278: 27-31.
57. Ray W. A., Fought R. L., Decker M. D. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol 1992; 136: 873-83.
58. Dassanayake T., Michie P., Carter G., Jones A. Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence. Drug Saf 2011; 34: 125-56.
59. Maxwell H. G., Dubois S., Weaver B., Bédard M. The additive effects of alcohol and benzodiazepines on driving. Can J Public Health 2010; 101: 353-7.
60. Paton C. Benzodiazepines and disinhibition: a review. Psychiatr Bull 2002; 26: 460-2.
61. Bond A. J. Drug-induced behavioural disinhibition. Incidence, mechanisms and therapeutic implications. CNS Drugs 1998; 9: 41-57.
62. Mahe V., Balogh A. Long-term pharmacological treatment of generalised anxiety disorder. Int Clin Psychopharmacol 2000; 15: 999-105.
63. Baldwin D. S., Polkinghorn C. Evidence-based pharmacotherapy of generalized anxiety disorder. Int J Neuropsychopharmacol 2005; 8: 293-302.
64. McLeod D. R., Hoehn-Saric R., Labib A. S., Greenblatt D. J. Six weeks of diazepam treatment in normal women: effects on psychomotor performance and psychophysiology. J Clin Psychopharmacol 1988; 8: 83-99.
65. Authier N., Balayssac D., Sautereau M., Zangarelli A., Courty P., Somogyi A. A. etal. Benzodiazepine dependence: focus on withdrawal syndrome. Ann Pharm Fr 2009; 67: 408-13.
66. Paltiel O., Marzec-Boguslawska A., Soskolne V., Massalha S., Avitzour M., Pfeffer R. etal. Use of tranquilizers and sleeping pills among cancer patients is associated with a poorer quality of life. Qual Life Res 2004; 13: 1699-706.
67. Bain K. T. Management of chronic insomnia in elderly persons. Am J Geriatr Pharmacother 2006; 4: 168-92.
68. Belleville G., Morin C. M. Hypnotic discontinuation in chronic insomnia: impact of psychological distress, readiness to change, and self-efficacy. Health Psychol 2008; 27: 239-48.
69. Ashton H. Benzodiazepine withdrawal: outcome in 50 patients. Br J Addict 1987; 82: 655-71.
70. Michelini S., Cassano G. B., Frare F., Perugi G. Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders. Pharmacopsychiatry 1996; 29: 127-34.
71. Burke K. C., Meek W. J., Krych R., Nisbet R., Burke J. D. Medical services use by patients before and after detoxification from benzodiazepine dependence. Psychiatr Serv 1995; 46: 157-60.
72. Cohen S. I. Alcohol and benzodiazepines generate anxiety, panic and phobias. J R Soc Med 1995; 88: 73-7.
73. Stewart S. A. The effects of benzodiazepines on cognition. J Clin Psychiatry 2005; 66: 9-13.
74. Tönne U., Hiltunen A. J., Vikander B., Engelbrektsson K., Bergman H., Bergman I. etal. Neuropsychological changes during steady-state drug use, withdrawal and abstinence in primary benzodiazepine-dependent patients. Acta Psychiatr Scand 1995; 91: 299-304.
75. Gorenstein C., Bernik M. A., Pompeia S., Marcourakis T. Impairment of performance associated with longterm use of benzodiazepines. J Psychopharmacol 1995; 9: 313-18.
76. McAndrews M. P., Weiss R. T., Sandor P., Taylor A., Carlen P. L., Shapiro C. M. Cognitive effects of long-term benzodiazepine use in older adults. Hum Psychopharmacol 2003; 18: 51-7.
77. Lader M. Benzos and memory loss: more than just 'old age'. Prescriber 1992; 3: 13.
78. Klein-Schwartz W., Oderda G. M. Poisoning in the elderly. Epidemiological, clinical and management considerations. Drugs Aging 1991; 1: 67-89.
79. Starr J. M., Whalley L. J. Drug-induced dementia. Incidence, management and prevention. Drug Saf 1994; 11: 310-7.
80. Lechin F., van der Dijs B., Benaim M. Benzodiazepines: tolerability in elderly patients. Psychother Psychosom 1996; 65: 171-82.
81. Hulse G. K., Lautenschlager N. T., Tait R. J., Almeida O. P. Dementia associated with alcohol and other drug use. Int Psychogeriatr 2005; 17: S109-27.
82. Wu C. S., Wang S. C., Chang I. S., Lin K. M. The association between dementia and long-term use of benzodiazepine in the elderly: nested case-control study using claims data. Am J Geriatr Psychiatry 2009; 17: 614-20.
83. Bierman E. J., Comijs H. C., Gundy C. M., Sonnenberg C., Jonker C., Beekman A. T. The effect of chronic benzodiazepine use on cognitive functioning in older persons: good, bad or indifferent? Int J Geriatr Psychiatry 2007; 22: 1194-200.
84. Lagnaoui R., Bégaud B., Moore N., Chaslerie A., Fourrier A., Letenneur L. etal. Benzodiazepine use and risk of dementia: a nested case-control study. J Clin Epidemiol 2002; 55: 314-8.
85. Poyares D., Guilleminault C., Ohayon M. M., Tufik S. Chronic benzodiazepine usage an withdrawal in insomnia patients. J Psychiatr Res 2004; 38: 327-34.
86. Barter G., Cormack M. The long-term use of benzodiazepines: patients' views, accounts and experiences. Fam Pract 1996; 13: 491-7.
87. Lechin F., van der Dijs B., Vitelli-Flores G., Báez S., Lechin M. E., Lechin A. E. etal. Peripheral blood immunological parameters in long-term benzodiazepine users. Clin Neuropharmacol 1994; 17: 63-72.
88. Wakakura M., Tsubouchi T., Inouye J. Etizolam and benzodiazepine induced blepharospasm. J Neurol Neurosurg Psychiatry 2004; 75: 506-7.
89. Neiman J. Alcohol as a risk factor for brain damage: neurologic aspects. Alcohol Clin Exp Res 1998; 2: 346S-51S.
90. Ron M. A., Acker W., Lishman W. A., Shaw G. K. Computerised tomography scan changes in chronic alcoholics: a survey and follow-up study. Brain 1982; 105: 497-514.
91. Lader M., Ron M., Petursson H. Computed axial brain tomography in long-term benzodiazepine users. Psychol Med 1984; 14: 203-6.
92. Moodley P., Golombok S., Shine P., Lader M. Computed axial brain tomograms in long-term benzodiazepine users. Psychiatry Res 1993; 48: 135-44.
93. Schmauss C., Krieg J.-C. Enlargement of cerebrospinal fluid spaces in long-term benzodiazepine abusers. Psychol Med 1987; 17: 869-73.
94. Uhde T. W., Kellner C. H. Cerebral ventricular size in panic disorder. J Affect Disord 1987; 12: 175-8.
95. Borg S., Bergman H., Engelbrektson K., Vikander B. Dependence on sedative-hypnotics: neuropsychological impairment, field dependence and clinical course in a 5-year follow-up study. Br J Addict 1989; 84: 547-53.
96. Kitabayashi Y., Ueda H., Narumoto J., Iizumi H., Tsuchida H., Murata N. etal. Chronic high-dose nitrazepam dependence 123I-IMP SPECT and EEG studies. Addict Biol 2001; 6: 257-61.
97. Perera K. M. H., Powell T., Jenner F. A. Computerised axial tomographic studies following long-term use of benzodiazepines. Psychol Med 1987; 17: 775-7.
98. Busto U. E. R., Bremner K. E., Knight K., ter Brugge K., Sellers E. M. Long-term benzodiazepine therapy does not result in brain abnormalities. J Clin Psychopharmacol 2000; 1: 2-6.
99. Woolas P. United Kingdom: Hansard, UK 1999. Available at: (accessed 3 August 2011; archived by Webcite at).
100. Behan M., Dobbin J. AddictionToday.org 2009. Available at: (accessed 3 August 2011; archived by Webcite at).
101. Lakhani N. Drugs Linked to Brain Damage 30 Years Ago. United Kingdom: Independent on Sunday. 2010. Available at: (accessed 3 August 2011; archived by Webcite at).
102. Reed K., Bond A., Witton J., Cornish R., Hickman M., Strang J. The Changing Use of Prescribed Benzodiazepines and z-Drugs and of over-the-Counter Codeine-Containing Products in England: A Structured Review of Published English and International Evidence and Available Data to Inform Consideration of the Extent of Dependence and Harm 2011. Available at: (accessed 3 August 2011; archived by Webcite at).
103. Preston K., Griffiths R., Cone E., Darwin W., Gorodetzky C. Diazepam and methadone blood levels following concurrent administration of diazepam and methadone. Drug Alcohol Depend 1986; 18: 195-202.
104. Farre M., Teran M., Roset P., Mas M. Abuse liability of flunitrazepam among methadone-maintained patients. Psychopharmacology 1998; 140: 486-95.
105. Lintzeris N., Mitchell T. B., Bond A. J., Nestor L., Strang J. Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients. Drug Alcohol Depend 2007; 91: 187-94.
106. Lintzeris N., Mitchell T. B., Bond A. J., Nestor L., Strang J. Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients. J Clin Psychopharmacol 2006; 26: 274-83.
107. Oliver P., Keen J. Concomitant drugs of misuse and drug using behaviours associated with fatal opiate-related poisonings in Sheffield, UK, 1997-2000. Addiction 2004; 98: 191-7.
108. Pirnay S., Borron S., Giudicelli C., Tourneau J., Baud F., Ricordel I. A critical review of the causes of death among post-mortem toxicological investigations: analysis of buprenorphine-associated and 35 methadone-associated deaths. Addiction 2004; 99: 978-88.
109. Charlson F. L., Degenhardt L., McLaren J., Hall W., Lynskey M. A systematic review of research examining benzodiazepine-related mortality. Pharmacoepidemiol Drug Saf 2009; 18: 93-103.
110. Ostini R., Jackson C., Hegney D., Tett S. E. How is medication prescribing ceased? A systematic review. Med Care 2011; 49: 24-36.
111. Levine D. A. 'Pharming': the abuse of prescription and over-the-counter drugs in teens. Curr Opin Pediatr 2007; 19: 270-4.
112. Hollister L. E., Motzenbecker F. P., Degan R. O. Withdrawal reactions to chlordiazepoxide ('Librium'). Psychopharmacologia 1961; 2: 63-8.
113. Scharf M. B., Kales A., Bixler E. O., Jacoby J. A., Schweitzer P. K. Lorazepam-efficacy, side effects, and rebound phenomena. Clin Pharmacol Ther 1982; 31: 175-9.
114. Walsh J. K., Schweitzer P. K., Parwatikar S. Effects of lorazepam and its withdrawal on sleep, performance, and subjective state. Clin Pharmacol Ther 1983; 34: 496-500.
115. Kales A., Bixler E. O., Soldatos C. R., Jacoby J. A., Kales J. D. Lorazepam: effects on sleep and withdrawal phenomena. Pharmacology 1986; 32: 121-30.
116. Bonnet M. H., Arand D. L. The use of lorazepam TID for chronic insomnia. Int Clin Psychopharmacol 1999; 14: 81-9.
117. Adam K., Oswald I. Can a rapidly-eliminated hypnotic cause daytime anxiety? Pharmacopsychiatry 1989; 22: 115-9.
118. Fontaine R., Beaudry P., Le Morvan P., Beauclair L., Chouinard G. Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety. Int Clin Psychopharmacol 1990; 5: 173-83.
119. MacKinnon G. L., Parker W. A. Benzodiazepine withdrawal syndrome: a literature review and evaluation. Am J Drug Alcohol Abuse 1982; 9: 19-33.
120. Ashton C. H. Benzodiazepines: How They Work and How to Withdraw (revised edition 2011). Newcastle: University of Newcastle; 2002.
121. Higgitt A., Fonagy P., Toone B., Shine P. The prolonged benzodiazepine withdrawal syndrome: anxiety or hysteria? Acta Psychiatr Scand 1990; 89: 165-8.
122. Hallstrom C., Lader M. H. Benzodiazepine withdrawal phenomena. Int Pharmacopsychiatry 1981; 16: 235-44.
123. Lader M. Long-term anxiolytic therapy: the issue of drug withdrawal. J Clin Psychiatry 1987; 48: 12-6.
124. Lader M. Withdrawal reactions after stopping hypnotics in patients with insomnia. CNS Drugs 1998; 10: 425-40.
125. Petursson H., Lader M. Dependence on Tranquillizers. Maudsley Monograph no. 28. Oxford: Oxford University Press; 1984.
126. O'Connor K., Belanger L., Marchand A., Dupuis G., Elie R., Boyer R. Psychological distress and adaptational problems associated with discontinuation of benzodiazepines. Addict Behav 1999; 24: 517-41.
127. O'Connor K., Marchand A., Belanger L., Mainguy N., Landry P., Savard P. etal. Psychological distress and adaptational problems associated with benzodiazepine withdrawal and outcome: a replication. Addict Behav 2004; 29: 583-93.
128. Saxon L., Hjemdahl P., Hiltunen A. J., Borg S. Effects of flumazenil in the treatment of benzodiazepine withdrawal-a double-blind pilot study. Psychopharmacology 1997; 131: 153-60.
129. Smith D. E., Wesson D. R. Benzodiazepine dependency syndromes. J Psychoact Drugs 1983; 15: 85-95.
130. Landry M. J., Smith D. E., McDuff D. R., Baughman O. L. Benzodiazepine dependence and withdrawal: identification and medical management. J Am Board Fam Pract 1992; 5: 167-75.
131. Vikander B., Koechling U. M., Borg S., Tönne U., Hiltunen A. J. Benzodiazepine tapering: a prospective study. Nord J Psychiatry 2010; 64: 273-82.
132. Kan C. C., Breteler M. H. M., Zitmann F. G. High prevalence of benzodiazepine dependence in out-patient users, based on the DSM-III-R and ICD-10 criteria. Acta Psychiatr Scand 1997; 96: 85-93.
133. Russell V. J., Lader M. Guidelines for the Prevention and Treatment of Benzodiazepine Dependence. London: Mental Health Foundation; 1993.
134. Lader M., Tylee A., Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs 2009; 23: 19-34.
135. De Gier N., Gorgels W., Lucassen P., Voshaar O. R., Mulder J., Zitman F. Discontinuation of long-term benzodiazepine use: 10-year follow-up. Fam Pract 2011; 28: 253-9.
136. Jørgensen V. R. K. An approach to reduce benzodiazepine and cyclopyrrolone use in general practice. CNS Drugs 2007; 21: 947-55.
137. Voshaar R. C., Couvee J. E., van Balkom A. J., Mulder P. G., Zitman F. G. Strategies for discontinuing long-term benzodiazepine use: meta-analysis. Br J Psychiatry 2006; 189: 213-20.
138. Denis D. C., Fatséas M., Lavie E., Auriacombe M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev 2006; 3: CD005194.
139. Higgitt A. C., Lader M. H., Fonagy P. Clinical management of benzodiazepine dependence. Br Med J 1985; 291: 688-90.
140. Sullivan M., Toshima M., Lynn P., Roy-Byrne P. Phenobarbital versus clonazepam for sedative-hypnotic taper in chronic pain patients. A pilot study. Ann Clin Psychiatry 1993; 5: 123-8.
141. Rickels K., DeMartinis N., Rynn M., Mandos L. Pharmacologic strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol 1999; 19: 12S-6S.
142. Zitman F. G., Couvee J. E. Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper-off. Report on behalf of the Dutch Chronic Benzodiazepine Working Group. Br J Psychiatry 2001; 178: 317-24.
143. Spiegel D. A. Psychological strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol 1999; 19: 17S-22S.
144. Voshaar R. C., Gorgels W. J., Mol A. J., van Balkom A. J., van de Lisdonk E. H., Breteler M. H. etal. Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy; three-condition, randomised controlled trial. Br J Psychiatry 2003; 182: 498-504.
145. Gosselin P., Ladouceur R., Morin C. M., Dugas M. J., Baillargeon L. Benzodiazepine discontinuation among adults with GAD: a randomized trial of cognitive-behavioural therapy. J Consult Clin Psychol 2006; 74: 908-19.
146. Baillargeon L., Landreville P., Verreault R., Beauchemin J.-P., Grégoire J. P., Morin C. M. Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering; a randomized trial. Can Med Assoc J 2003; 169: 1015-20.
147. Ten Wolde G. B., Dijkstra A., van Empelen P., van den Hout W., Neven A. K., Zitman F. Long-term effectiveness of computer-generated tailored patient education on benzodiazepines: a randomized controlled trial. Addiction 2008; 103: 662-70.
148. Parr J. M., Kavanagh D. J., Cahill L., Mitchell G., Young R. M. Effectiveness of current treatment approaches for benzodiazepine discontinuation; a meta-analysis. Addiction 2008; 104: 13-24.
149. Smith A. J., Tett S. E. Improving the use of benzodiazepines-is it possible? A non-systematic review of interventions tried in the last 20 years. BMC Health Serv Res 2010; 10: 321-8.
150. Parr J. M., Kavanagh D. J., Young R. M., Mitchell G. Acceptability of cognitive-behaviour therapy via the Internet for cessation of benzodiazepine use. Drug Alcohol Rev 2011; 30: 306-14.
151. Vorma H., Naukkarinen H., Sarna S., Kuoppasalmi K. Treatment of out-patients with complicated benzodiazepine dependence: comparison of two approaches. Addiction 2002; 7: 851-9.
152. Heather N., Paton J., Ashton H. Predictors of response to brief intervention in general practice against long-term benzodiazepine use. Posted online on May 6, 2011. doi:10.3109/16066359.2011.569102. Accessed 7 June 2011.
153. Higgitt A., Fonagy P., Lader M. The natural history of tolerance to the benzodiazepines. Psychol Med Monogr Suppl 1988; 13: 1-55.
154. Crockford D., White W. D., Campbell B. Gabapentin use in benzodiazepine dependence and detoxification. Can J Psychiatry 2001; 46: 287.
155. Bourin M., Dailly E., Hascoet M. Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome. CNS Drug Rev 2004; 10: 219-20.
156. Lemoine P., Kermadi I., Garcia-Acosta S., Garay R. P., Dib M. Double-blind, comparative study of cyamemazine vs. bromazepam in the benzodiazepine withdrawal syndrome. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 131-7.
157. Ashton C. H., Rawlins M. D., Tyrer S. P. A double-blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. Br J Psychiatry 1990; 157: 232-8.
158. Schweizer E., Rickels K., Case W. G., Greenblatt D. J. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome. Arch Gen Psychiatry 1991; 48: 448-52.
159. Oulis P., Konstantakopoulos G., Kouzoupis A. V., Masdrakis V. G., Karakatsanis N. A., Karapoulios E. etal. Pregabalin in the discontinuation of long-term benzodiazepines use. Hum Psychopharmacol 2008; 23: 337-40.
160. Bobes J., Rubio G., Terán A., Cervera G., López-Gómez V., Vilardaga I. etal. Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice. Eur Psychiatry 2011. Epub ahead of print.
161. Liebrenz M., Boesch L., Stohler R., Caflisch C. Agonist substitution-a treatment alternative for high-dose benzodiazepine-dependent patients? Addiction 2010; 105: 1870-4.
162. Tyrer P. Benzodiazepine substitution for dependent patients-going with the flow. Addiction 2010; 105: 1875-6.
163. Soyka M. To substitute or not-optimal tactics for the management of benzodiazepine dependence. Addiction 2010; 105: 1876-7.
164. Gerra G., Giucasto G., Zaimovic A. Intravenous flumazenil following prolonged exposure to lormetazepam in humans: lack of precipitated withdrawal. Int Clin Psychopharmacol 1996; 11: 81-8.
165. Griffiths R. R., Evans S. M., Guarino J. J. Intravenous flumazenil following acute and repeated exposure to lorazepam in healthy volunteers: antagonism and precipitated withdrawal. J Pharmacol Exp Ther 1993; 265: 1163-74.
166. Mintzer M. Z., Stoller K. B., Griffiths R. R. A controlled study of flumazenil-precipitated withdrawal in chronic low-dose benzodiazepine users. Psychopharmacology 1999; 147: 200-9.
167. Whitwam J. G. Flumazenil: a benzodiazepine antagonist: many uses, possibly including withdrawal from benzodiazepines. BMJ 1988; 297: 999.
168. Lader M. H., Morton S. V. A pilot study of the effects of flumazenil on symptoms persisting after benzodiazepine withdrawal. J Psychopharmacol 1992; 6: 351-63.
169. Gerra G., Marcato A., Caccavari R., Fertonani-Affini G. Effectiveness of flumazenil (RO-15-1788) in the treatment of benzodiazepine withdrawal. Curr Ther Res 1993; 54: 580-7.
170. Gerra G., Zaimovic A., Giusti F., Moi G., Brewer C. Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo-controlled study. Addict Biol 2002; 7: 385-95.
171. Savic I., Widen L., Stone-Elander S. Feasibility of reversing benzodiazepine tolerance with flumazenil. Lancet 1991; 337: 133-7.
172. Hood S., O'Neil G., Hulse G. The role of flumazenil in the treatment of benzodiazepine dependence. Physiological and psychological profiles. J Psychopharmacol 2009; 23: 401-9.
173. Enato E., Moretti M., Koren G. The fetal safety of benzodiazepines: an updated meta-analysis. J Obstet Gynaecol Can 2011; 33: 46-8.
174. Einarson A., Selby P., Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci 2001; 26: 44-8.
175. McElhatton P. R. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol 1994; 8: 461-75.
176. UK Department of Health and the Devolved Administrations. Drug Misuse and Dependence: UK Guidelines on Clinical Management. London: Department of Health; 2007.
177. Lader M. H. Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? Eur Neuropsychopharmacol 1999; 9: S399-405.
178. Griffiths R. R., Weert E. M. Benzodiazepine self-administration in humans and laboratory animals-implications for problems of long-term use and abuse. Psychopharmacology 1997; 134: 1-37.
179. A receptor modulation and beyond. Pharmacol Biochem Behav 2008; 90: 74-89.
180. Karch S. B. Drug Abuse Handbook, 2nd edn. New York: CRC Press; 2006, p. 217.
181. International Narcotics Control Board. List of psychotropic substances under international control 2003. Accessed 7 June 2011.
182. Launchbury A. P., Drake J., Seager H. Misuse of temazepam. BMJ 1992; 305: 252-3.
183. Farré M., Camí J. Pharmacokinetic considerations in abuse liability evaluation. Br J Addict 1991; 86: 1601-6.
184. Busto U., Sellers E. M. Pharmacokinetic determinants of drug abuse and dependence. A conceptual perspective. Clin Pharmacokinet 1986; 11: 144-53.
185. Goodwin R. D., Hasin D. S. Sedative use and misuse in the United States. Addiction 2001; 97: 555-62.
186. Caan W., Belleroche J., editors. Benzodiazepine Abuse. Drink, Drugs and Dependence: From Science to Clinical Practice, 1st edn. London: Routledge; 2002, p. 197-211.
187. Martinez-Cano H., Vela-Bueno A., De Iceta M., Pomalima R., Martinez-Gras I., Sobrino M. P. Benzodiazepine types in high versus therapeutic dose dependence. Addiction 1996; 91: 1179-86.
188. De Wit H., Griffiths R. R. Testing the abuse liability of anxiolytic and hypnotic drugs in humans. Drug Alcohol Depend 1991; 28: 83-111.
189. Seivewright N. A., Dougal W. Benzodiazepine misuse. Curr Opin Psychiatry 1992; 5: 408-11.
190. Wolf B., Grohmann R., Biber D., Brenner P. M., Ruther E. Benzodiazepine abuse and dependence in psychiatric inpatients. Pharmacopsychiatry 1989; 22: 54-60.
191. Bergman U., Dahl-Puustinen M. L. Use of prescription forgeries in a drug abuse surveillance network. Eur J Clin Pharmacol 1989; 36: 621-3.
192. Peles E., Schreiber S., Adelson M. Tricyclic antidepressants abuse, with or without benzodiazepines abuse, in former heroin addicts currently in methadone maintenance treatment (MMT). Eur Neuropsychopharmacol 2007; 18: 188-93.
193. Walker B. M., Ettenberg A. The effects of alprazolam on conditioned place preferences produced by intravenous heroin. Pharmacol Biochem Behav 2003; 75: 75-80.
194. Darke S., Ross J., Cohen J. The use of benzodiazepines among regular amphetamine users. Addiction 1994; 89: 1683-90.
195. Stitzer M., Griffiths R., McLellan A., Grabowski J., Hawthorne J. Diazepam use among methadone maintenance patients: patterns and dosages. Drug Alcohol Depend 1981; 8: 189-99.
196. Williamson S., Gossop M., Powis B., Griffiths P., Fountain J., Strang J. Adverse effects of stimulant drugs in a community sample of drug users. Drug Alcohol Depend 1997; 4: 87-94.
197. Sheehan M. F., Sheehan D. V., Torres A., Coppola A., Francis E. Snorting benzodiazepines. Am J Drug Alcohol Abuse 1991; 17: 457-68.
198. Strang J., Griffiths P., Abbey J., Gossop M. Survey of injected benzodiazepines among drug users in Britain. BMJ 1994; 308: 1082.
199. Bond A. J., Seijas D., Dawling S., Lader M. H. Systematic absorption and abuse liability of snorted flunitrazepam. Addiction 1994; 89: 821-30.
200. Loxley W. Benzodiazepine use and harms among police detainees in Australia. In: Trends Issues Crime Criminal Justice. Canberra, ACT: Australian Institute of Criminology; 2007, p. 336.
201. Schwartz R. H., Milteer R., LeBeau M. A. Drug-facilitated sexual assault ('date rape'). South Med J 2000; 93: 558-61.
202. Goullé J. P., Anger J. P. Drug-facilitated robbery or sexual assault: problems associated with amnesia. Ther Drug Monit 2004; 26: 206-10.
203. National Treatment Agency for Substance Misuse. Addiction to Medicine: An Investigation into the Configuration and Commissioning of Treatment Services to Support Those Who Develop Problems with Prescription-Only or over-the Counter Medicine 2011. Available at: (accessed 3 August 2011; archived by Webcite at).
204. Galanter M., Kleber H. D. The American Psychiatric Publishing Textbook of Substance Abuse Treatment, 4th edn. Washington, DC: American Psychiatric Publishing Inc; 2008, p. 197.
205. NHS Information Centre for Health and Social Care. Adult Psychiatric Morbidity in England, 2007. London: National Centre for Social Research; 2009.
206. Ancoli-Israel S. Sleep and aging: prevalence of disturbed sleep and treatment considerations in older adults. J Clin Psychiatry 2005; 66: 24-30.
207. Lader M. Use of benzodiazepines in the aging population: do the benefits outweigh the risks? In: Pandi-Perumal S. R., Monti J. M., Monjan A. A., editors. Principles and Practice of Geriatric Sleep Medicine, Cambridge: Cambridge University Press; 2010, p. 362-70.
208. Donoghue J., Lader M. Usage of benzodiazepines; a review. Int J Psychiatry Clin Pract 2010; 14: 78-87.
209. Voyer P., Cohen D., Lauzon S., Collin J. Factors associated with psychotropic drug use among community-dwelling older persons: a review of empirical studies. BMC Nurs 2004; 3: 3-16.
210. Committee on the Review of Medicines. Systematic review of the benzodiazepines. BMJ 1980; 1: 910-12.
211. Katzman M. A. Current considerations in the treatment of Generalized Anxiety Disorder. CNS Drugs 2009; 23: 103-20.
212. Martin J. L., Sainz-Pardo M., Furukawa T. A., Martín-Sánchez E., Seoane T., Galán C. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol 2007; 21: 774-82.
213. Wright N., Caplan R., Payne S. Community survey of long term daytime use of benzodiazepines. BMJ 1994; 309: 27-8.
214. Ohayon M. M., Caulet M., Priest R. G., Guilleminault C. Psychotropic medication consumption patterns in the UK general population. J Clin Epidemiol 1998; 51: 273-83.
215. Siriwardena A. N., Qureshi Z., Gibson S., Collier S., Latham M. GPs' attitudes to benzodiazepine and 'Z-drug' prescribing: a barrier to implementation of evidence and guidance on hypnotics. Br J Gen Pract 2006; 56: 964-7.
216. Siriwardena A. N., Apekey T., Tilling M., Dyas J. V., Middleton H., Ørner R. General practitioners' preferences for managing insomnia and opportunities for reducing hypnotic prescribing. J Eval Clin Pract 2010; 16: 731-7.
217. Office of National Statistics. Psychiatric Morbidity among Adults Living in Private Households, 2000. London: HMSO; 2006.
218. Colman I., Wadsworth M. E., Croudace T. J., Jones P. B. Three decades of antidepressant, anxiolytic and hypnotic use in a national population birth cohort. Br J Psychiatry 2006; 189: 156-60.
219. Magrini N., Vaccheri A., Parma E., D'Alessandro R., Bottoni A., Occhionero M. etal. Use of benzodiazepines in the Italian general population: prevalence, pattern of use and risk factors for use. Eur J Clin Pharmacol 1996; 50: 19-25.
220. Ciuna A., Andretta M., Corbari L., Levi D., Mirandola M., Sorio A. etal. Are we going to increase the use of antidepressants up to that of benzodiazepines? Eur J Clin Pharmacol 2004; 60: 629-34.
221. Veronese A., Garatti M., Cipriani A., Barbui C. Benzodiazepine use in the real world of psychiatric practice: low-dose, long-term drug taking and low rates of treatment discontinuation. Eur J Clin Pharmacol 2007; 63: 867-73.
222. Chau N., Baumann M., Falissard B., Choquet M. and the Lorhandicap group. Correlates and inequalities of psychotropic drug use among young adults: a population-based questionnaire study. Int J Equity Health 2008; 7: 3-14.
223. van Hulten R., Teeuw K. B., Bakker A., Leufkens H. G. Initial 3-month usage characteristics predict long-term use of benzodiazepines: an 8-year follow-up. Eur J Clin Pharmacol 2003; 58: 689-94.
224. Zandstra S. M., Furer J. W., van de Lisdonk E. H., van't H. M., Bor J. H., van Weel C. etal. Different study criteria affect the prevalence of benzodiazepine use. Soc Psychiatry Psychiatr Epidemiol 2002; 37: 139-44.
225. Zandstra S. M., van Rijswijk E., Rijnders C. A. T., van de Lisdonk E. H., Bor J. H. J., van Weel C. etal. Long-term benzodiazepine users in family practice: differences from short-term users in mental health, coping behaviour and psychological characteristics. Fam Pract 2004; 21: 266-9.
226. van Rijswijk E., Borghuis M., van de Lisdonk E., Zitman F., van Weel C. Treatment of mental health problems in general practice: a survey of psychotropics prescribed and other treatments provided. Int J Clin Pharmacol Ther 2007; 45: 23-9.
227. Straand J., Rokstad K. General practitioners' prescribing patterns of benzodiazepine hypnotics: are elderly patients at particular risk for overprescribing? A report from the Møre & Romsdal Prescription Study. Scand J Prim Health Care 1997; 15: 16-21.
228. Lagnaoui R., Depont F., Fourrier A., Abouelfath A., Begaud B., Verdoux H. etal. Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol 2004; 60: 523-9.
229. Isacson D., Carsjo K., Bergman U., Blackburn J. L. Long-term use of benzodiazepines in a Swedish community: an eight-year follow-up. J Clin Epidemiol 1992; 45: 429-36.
230. van Hulten R., Isacson D., Bakker A., Leufkens H. G. Comparing patterns of long-term benzodiazepine use between a Dutch and a Swedish community. Pharmacoepidemiol Drug Saf 2003; 12: 49-53.
231. Hausken A. M., Furu K., Skurtveit S., Engeland A., Bramness J. G. Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors. Eur J Clin Pharmacol 2009; 65: 295-301.
232. Ohayon M. M., Lader M. H. Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. J Clin Psychiatry 2002; 63: 817-25.
233. Alfonso J., Ferrer M., Romera B., Vilagut G., Angermeyer M., Bernert S. etal. The European Study of the Epidemiology of Mental Misorders (ESEMeD/MHEDEA 2000) project: rationale and methods. Int J Methods Psychiatr Res 2002; 11: 55-6.
234. Kessler R. C. The global burden of anxiety and mood disorders: putting ESEMeD findings into perspective. J Clin Psychiatry 2007; 68: 10-9.
235. Vasile R. G., Bruce S. E., Goisman R. M., Pagano M., Keller M. B. Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in treatment of Generalized Anxiety Disorder and Social Phobia. Depress Anxiety 2005; 22: 59-67.
236. Neutel C. I. The epidemiology of long-term benzodiazepine use. Int Rev Psychiatry 2005; 17: 189-97.
237. Smith A. J., Sketris I., Cooke C., Gardner D., Kisely S., Tett S. E. A comparison of benzodiazepine and related drug use in Nova Scotia and Australia. Can J Psychiatry 2008; 53: 545-52.
238. Omvik S., Pallesen S., Bjorvatn B., Sivertsen B., Havik O. E., Nordhus I. H. Patient characteristics and predictors of sleep medication use. Int Clin Psychopharmacol 2010; 25: 91-100.
239. Victorri-Vigneau C., Dailly E., Veyrac C., Jolliet P. Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol 2007; 64: 198-209.
240. Petitjean S., Ladewig D., Meier C. R., Amrein R., Wiesbeck G. A. Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. Int Clin Psychopharmacol 2007; 22: 292-8.
241. Boeuf-Cazou O., Niezbotala M., Marquie J. C., Lapeyre-Mestre M. Factors associated with psychoactive drug initiation in a sample of workers in France: results of the VISAT cohort study. Pharmacoepidemiol Drug Saf 2010; 19: 296-305.
242. Straand J., Rokstad K. S. Elderly patients in general practice: diagnoses, drugs and inappropriate prescriptions. A report from the Møre & Romsdal Prescription Study. Fam Pract 1999; 16: 380-8.
243. Tu K., Mamdani M. M., Hux J. E., Tu J. B. Progressive trends in the prevalence of benzodiazepine prescribing in older people in Ontario, Canada. J Am Geriatr Soc 2001; 49: 1341-5.
244. Aparasu R. R., Mort J. R., Brandt H. Psychotropic prescription use by community-dwelling elderly in the United States. J Am Geriatr Soc 2003; 51: 671-7.
245. Aparasu R. R., Mort J. R. Prevalence, correlates, and associated outcomes of potentially inappropriate psychotropic use in the community-dwelling elderly. Am J Geriatr Pharmacother 2004; 2: 102-11.
246. Linden M., Bär T., Helmchen H. Prevalence and appropriateness of psychotropic drug use in old age; results from the Berlin Aging Study (BASE). Int Psychogeriatr 2004; 16: 461-80.
247. Luijendijk H. J., Tiermeier H., Hofman A., Heeringa J., Stricker B. H. C. Determinants of chronic benzodiazepine use in the elderly: a longitudinal study. Br J Clin Pharmacol 2007; 65: 593-9.
248. Windle A., Elliot E., Duszynski K., Moore V. Benzodiazepine prescribing in elderly Australian general practice patients. Aust NZ J Public Health 2007; 31: 379-81.
249. Millar H. L., Clunie F. S., McGilchrist M. M., McMahon A. D., MacDonald T. M. The impact on community benzodiazepine prescribing of hospitalization. J Psychosom Res 1997; 42: 61-9.
250. Fourrier A., Letenneur L., Dartigues J. F., Moore N., Bégaud B. Benzodiazepine use in an elderly community-dwelling population Characteristics of users and factors associated with subsequent use. Eur J Clin Pharmacol 2001; 57: 419-25.
251. Spanemberg L., Nogueira E. L., da Silva C. T., Dargél A. A., Menezes F. S., Cataldo Neto A. High prevalence and prescription of benzodiazepines for elderly: data from psychiatric consultation to patients from an emergency room of a general hospital. Gen Hosp Psychiatry 2011; 33: 45-50.
252. Valenstein M., Taylor K. K., Austin K., Kales H. C., McCarthy J. F. etal. Benzodiazepine use among depressed patients treated in mental health settings. Am J Psychiatry 2004; 161: 654-61.
253. Mancini J., Thirion X., Masut A., Saillard C., Pradel V., Romain F. etal. Anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002. Pharmacoepidemiol Drug Saf 2006; 15: 494-503.
254. Jorm A. F., Grayson D., Creasey H., Waite L., Broe G. A. Long-term benzodiazepine use by elderly people living in the community. Aust NZ J Public Health 2000; 24: 7-10.
255. Flovig J. C., Vaaler A. E., Morken G. Effects of legal and illegal use of benzodiazepines at acute admission to a psychiatric acute department. BMC Res Notes 2010; 3: 263-71.
256. Manthey L., Van Veen T., Giltay E. J., Stoop J. E., Neven A. K., Penninx B. W. etal. Correlates of (inappropriate) benzodiazepine use: the Netherlands Study of Depression and Anxiety (NESDA). Br J Clin Pharmacol 2011; 71: 263-72.
257. National Institute for Health and Clinical Excellence. Anxiety. Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults. Clinical Guideline 113. London: National Institute for Health and Clinical Excellence; January 2011.
258. Tyrer P. The benzodiazepine bonanza. Lancet 1974; 2: 709-10.
259. Lader M. Benzodiazepines-the opium of the masses? Neuroscience 1978; 3: 159-65.
260. Gabe J., Gustafsson U., Bury M. Mediating illness: newspaper coverage of tranquilliser dependence. Sociol Health Illn 1991; 13: 332-53.
261. Speaker S. L. From 'happiness pills' to 'national nightmare': changing cultural assessment of minor tranquilizers in America, 1955-1980. J Hist Med Allied Sci 1997; 52: 338-72.
262. Marshall K. P., Georgievskava Z., Georgievsky I. Social reactions to Valium and Prozac: a cultural lag perspective of drug diffusion and adoption. Res Social Adm Pharm 2009; 5: 94-107.
263. Rosenbaum J. F. Attitudes toward benzodiazepines over the years. J Clin Psychiatry 2005; 66: 4-8.
264. Anthierens S., Habraken H., Petrovic M., Christiaens T. The lesser evil? Initiating a benzodiazepine prescription in general practice: a qualitative study on GPs' perspectives. Scand J Prim Health Care 2007; 25: 214-9.
265. El-Guabaly N., Sareen J., Stein M. B. Are there guidelines for the responsible prescriptions of benzodiazepines? Can J Psychiatry 2010; 55: 709-14.
266. Haw C., Stubbs J. Benzodiazepines-a necessary evil? A survey of prescribing at a specialist UK psychiatric hospital. J Psychopharmacol 2007; 21: 645-9.
267. Cook J. M., Marshall R., Masci C., Coyne J. C. Physicians' perspectives on prescribing benzodiazepines in older adults: a qualitative study. J Gen Intern Med 2007; 22: 303-7.
268. Cook J. M., Biyanova T., Masci C., Coyne J. C. Older patient perspectives on long-term anxiolytic benzodiazepine use and discontinuation: a qualitative study. J Gen Intern Med 2007; 22: 1094-100.
269. Sussman N. Treating anxiety while minimizing abuse and dependence. J Clin Psychiatry 1993; 54: 44-51.
270. Logan K. E., Lawrie S. M. Long term use of hypnotics and anxiolytics may not result in increased tolerance. BMJ 1994; 309: 742-3.
271. Cloos J. M., Ferreira V. Current use of benzodiazepines in anxiety disorders. Curr Opin Psychiatry 2009; 22: 90-5.
272. National Center on Addiction and Substance Abuse at Columbia University. You've Got Drugs! Prescription Drug Pushers on the Internet. New York: Columbia University; 2006 update.
273. King M. B. Is there still a role for benzodiazepines in general practice? Br J Gen Pract 1992; 42: 202-5.
274. O'Brien C. P. Benzodiazepine use, abuse and dependence. J Clin Psychiatry 2005; 66: 28-33.
275. Prescription Services Division of the NHS Business Services Authority. Available at: (accessed 7 June 2011).
276. Olajide D., Lader M. Depression following withdrawal from long-term benzodiazepine use: a report of four cases. Psychol Med 1984; 14: 937-40.
277. Batty G. M., Osborne C. A., Swift C. G., Jackson S. H. Development of an indicator to identify inappropriate use of benzodiazepines in elderly medical in-patients. Int J Geriatr Psychiatry 2000; 15: 892-6.